At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
alemtuzumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study
In Brief
A Phase 2 clinical trial evaluating alemtuzumab and everolimus for Lymphocytic Leukemia. Completed, enrolled 28 participants across 2 sites.
Detailed Summary
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the signaling molecules needed for cell growth. Monoclonal antibodies, such as alemtuzumab, can bind to and kill malignant lymphocytes. PURPOSE: This phase I/II trial is studying the side effects and best dose of everolimus when given together with alemtuzumab and will see how well they work in treating patients with recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphocytic Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionDec 2015
TodayJul 2026
First PostedJul 9, 2009
Enrollment StartJul 1, 2009
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 17.0 years ago
Interventions
alemtuzumabdrug
Given subcutaneously
everolimusdrug
Given orally